The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of inflammatory and nutritional (IN) status on induction chemotherapy (CT) followed by chemoradiotherapy (CRT) for locally advanced pancreatic cancer (LAPC): An exploratory subgroup analysis of JCOG1106.
 
Nobumasa Mizuno
Honoraria - Kyowa Hakko Kirin; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
 
Akira Fukutomi
Honoraria - Daiichi Sankyo; Lilly Japan; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Yakult Honsha
Research Funding - Merck Serono (Inst); NanoCarrier (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Junki Mizusawa
No Relationships to Disclose
 
Hiroshi Katayama
No Relationships to Disclose
 
Satoaki Nakamura
No Relationships to Disclose
 
Yoshinori Ito
No Relationships to Disclose
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Tatsuya Ioka
Consulting or Advisory Role - AstraZeneca; Baxalta; Taiho Pharmaceutical; Yakult Honsha
Speakers' Bureau - Daiichi Sankyo; Eisai; Fujifilm; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Nihon Zouki (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Lilly; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Eisai
Research Funding - AstraZeneca; Daiichi Sankyo; Eisai; Merck Serono; MSD; NanoCarrier; Ono Pharmaceutical; Shire; Taiho Pharmaceutical; Zeria Pharmaceutical
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Nippon Kayaku; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb; Eisai; Kyowa Hakko Kirin; Lilly Japan; NanoCarrier
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxter; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Kazuya Sugimori
No Relationships to Disclose
 
Kyoko Shimizu
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - AstraZeneca Japan; Baxter; Bayer Yakuhin; Celgene; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Fujifilm; Lilly Japan; Merck Serono; Nippon Chemiphar; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly Japan; Nippon Boehringer Ingelheim; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan; Baxter; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; GlaxoSmithKline K.K.; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Shizuoka Industry; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
 
Masato Ozaka
Honoraria - Bayer; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Shoji Nakamori
Research Funding - Eisai
 
Takeshi Azuma
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Bayer; Churchill Pharmaceuticals; Eisai; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Churchill Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Taiho Pharmaceutical (Inst)
 
Hiroshi Ishii
Honoraria - Hospira; Kyowa Hakko Kirin; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Nobelpharma; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Shionogi; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; J-Pharma; Janssen; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; NanoCarrier; Novartis; OncoTherapy Science; Ono Pharmaceutical; Shionogi; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha; Zeria Pharmaceutical